Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Drops By 52.7%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large decrease in short interest in November. As of November 30th, there was short interest totalling 26,700 shares, a decrease of 52.7% from the November 15th total of 56,500 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 26,800 shares, the days-to-cover ratio is currently 1.0 days.

SOPHiA GENETICS Stock Down 2.4 %

NASDAQ SOPH opened at $3.32 on Thursday. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The company has a market cap of $217.05 million, a price-to-earnings ratio of -3.05 and a beta of 0.99. The company has a 50 day moving average of $3.44 and a 200-day moving average of $3.98. SOPHiA GENETICS has a 1-year low of $2.70 and a 1-year high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The company had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. During the same period last year, the company posted ($0.21) earnings per share. On average, equities research analysts expect that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently made changes to their positions in SOPH. Banque Cantonale Vaudoise raised its stake in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after acquiring an additional 9,000 shares in the last quarter. Green Alpha Advisors LLC acquired a new position in SOPHiA GENETICS during the 3rd quarter worth approximately $79,000. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after purchasing an additional 86,764 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.